The initial focus of the CGT Access Model will be on Sickle Cell Disease (SCD), a genetic blood disorder that predominantly affects Black Americans, impacting over 100,000 people in the U.S. SCD patients often endure severe pain, leading to frequent hospitalizations, and have a life expectancy 20 years shorter than the national average.
AIR’s role will be crucial in monitoring the implementation and outcomes of the CGT Access Model. The organization will develop and execute a comprehensive data collection and analysis plan to assess both health outcomes and financial indicators. AIR’s efforts will also include disseminating findings at conferences to foster innovation in the field.
“The Cell and Gene Therapy Access Model has the potential to make groundbreaking treatments more widely available to those who need them and reduce long-term healthcare costs,” said Timothy Hill, AIR senior vice president, who leads the institution’s Health Division. “We look forward to working with CMS and our partners to test innovative solutions that can improve people’s lives and create a more equitable world.”
https://www.globenewswire.com/news-release/2024/08/21/2933709/0/en/American-Institutes-for-Research-To-Help-Implement-Federal-Program-Aimed-at-Increasing-Access-to-Transformative-Cell-and-Gene-Therapy-Treatments.html
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
AAV Gene Therapy Revolutionizes Treatment for LCA1, Improving Vision Significantly
Innovative AAV Gene Therapy Dramatically Restores Vision in LCA1 Researchers have made a significant breakthrough in treating Leber congenital amaurosis type 1 (LCA1), a severe inherited retinal disease that causes early childhood blindness, by using an innovative...
Cellular Origins & 3P Innovation Partner to Streamline Cell and Gene Therapy Manufacturing
Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), has partnered with 3P innovation, an engineering company and supplier of automated fill-finish equipment, to integrate 3P...
Voyager Therapeutics Expands Gene Therapy Portfolio with Novartis License for Next-Generation Capsid
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company focused on neurogenetic medicines, has entered into a licensing agreement with Novartis AG (NYSE: NVS) for a novel capsid developed using Voyager’s TRACER™ capsid discovery platform. This license will...
BridgeBio ends development of gene therapy for adrenal gland disorder
BridgeBio said Tuesday night it won’t move forward with a gene therapy for a group of genetic disorders that impair adrenal glands and cause disruptions in producing cortisol. The California biotech made the decision because Phase 1/2 data were “not yet...
Related Services
Plasmids GMP Services
AAV GMP Services
